Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal natural killer (NK) cell therapies, including IBR854, IBR733, IBR822, and IBR900, as well as the market launch of peripheral blood-derived, non-viral vector, non-gene edited off-the-shelf universal immune domestication NK/CAR raNK and tiNK cell products.
Platform and Pipeline Development
Founded in 2014, iMBIORAY has established a robust platform for developing innovative cell therapies. The company’s platforms include the CAR-raNK-ADC platform for introducing CARs into NK cells, the tiNK immune domestication NK cell platform, the ANKERTM antibody-guided NK connector platform, and mRNA vaccine technology. These platforms position iMBIORAY at the forefront of developing next-generation NK cell therapies.
Future Outlook
With the Series A+ financing, iMBIORAY is poised to accelerate its clinical programs and bring its universal NK cell therapies closer to market. The funding will support the development of its lead candidates and the commercialization of its off-the-shelf NK cell products, addressing significant unmet needs in oncology and immunotherapy.-Fineline Info & Tech
